Fig. 4.

Quantification of c-Fos immunoreactivity across brain regions. A: regions showing a main effect of DOCA-salt treatment, which was significantly moderated by benzamil treatment (P < 0.05, *significant difference from Vehicle-Vehicle, +significant difference from Benzamil-DOCA). In all cases, DOCA-salt treatment increased c-Fos immunoreactivity, while benzamil treatment reduced this effect. This effect was seen most dramatically in the pmPVN neurons, but was also observed in the supraoptic nucleus (SON) and in mpPVN neurons. Note that counts in pmPVN and SON reflect only double-labeled neurons. B: regions showing a main effect of DOCA-salt treatment (P < 0.05), with no response to ICV benzamil (P < 0.05, *significant difference from Vehicle-Vehicle). DOCA-salt treatment increased c-Fos immunoreactivity in the dorsal parvocellular PVN, the ventrolateral parvocellular PVN, and in the more posterior mixed region of caudal parvocellular PVN neurons (containing both medial and lateral parvocellular neurons). C: regions that did not respond to DOCA-salt treatment with increased c-Fos immunoreactivity. We observed no group differences in c-Fos immunoreactivity within the median preoptic nucleus (MnPO), the rostroventrolateral medulla (RVLM), the nucleus ambiguous, the dorsal motor nucleus of the vagus nerve, or the nucleus of the tractus solitarius. DMX, dorsal motor nucleus of the vagus nerve; NTS, nucleus of the tractus solitarius.